Tobira Therapeutics Inc  

(Public, NASDAQ:TBRA)   Watch this stock  
Find more results for Carol J. Cooper´┐Ż
-0.35 (-7.78%)
After Hours: 4.45 +0.30 (7.23%)
Jul 26, 6:15PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.03 - 4.70
52 week 4.03 - 15.63
Open 4.70
Vol / Avg. 1.03M/221,834.00
Mkt cap 45.55M
P/E     -
Div/yield     -
EPS -1.44
Shares 18.82M
Beta     -
Inst. own 0%
Aug 9, 2016
Q2 2016 Tobira Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 25, 2016
Tobira Therapeutics Inc Conference call to Discuss CENTAUR Phase 2b Trial Results
Jun 21, 2016
Tobira Therapeutics Inc at JMP Securities Life Sciences Conference
Jun 9, 2016
Tobira Therapeutics Inc at Jefferies Healthcare Conference
May 9, 2016
Q1 2016 Tobira Therapeutics Inc Earnings Call
May 9, 2016
Q1 2016 Tobira Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -153.93% -234.93%
Return on average equity - -
Employees 11 -
CDP Score - -


701 Gateway Blvd Ste 300
United States - Map
+1-650-7416625 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Tobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.

Officers and directors

Dennis G. Podlesak Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Laurent Fischer M.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Christopher Peetz Chief Financial Officer
Age: 36
Bio & Compensation  - Reuters
Helen Jenkins Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Ian Clements Ph.D. Vice President of Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
Eric Lefebvre M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Carol L. Brosgart M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Jeffrey H. Cooper CPA Independent Director
Age: 59
Bio & Compensation  - Reuters
Andrew J. Fromkin Independent Director
Bio & Compensation  - Reuters
Patrick J. Heron Independent Director
Age: 44
Bio & Compensation  - Reuters